WO2017065473A1 - Oxadiazole amine derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same - Google Patents

Oxadiazole amine derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same Download PDF

Info

Publication number
WO2017065473A1
WO2017065473A1 PCT/KR2016/011355 KR2016011355W WO2017065473A1 WO 2017065473 A1 WO2017065473 A1 WO 2017065473A1 KR 2016011355 W KR2016011355 W KR 2016011355W WO 2017065473 A1 WO2017065473 A1 WO 2017065473A1
Authority
WO
WIPO (PCT)
Prior art keywords
amine
pyrimidin
oxadiazol
cyclobutyl
difluoromethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2016/011355
Other languages
English (en)
French (fr)
Inventor
Yuntae Kim
Chang Sik Lee
Jung Taek Oh
Hyeseung SONG
Jin Choi
Jaeyoung Lee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chong Kun Dang Corp
Original Assignee
Chong Kun Dang Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP2018518487A priority Critical patent/JP6697074B2/ja
Priority to ES16855690T priority patent/ES2940413T3/es
Priority to PL16855690.0T priority patent/PL3362445T3/pl
Priority to DK16855690.0T priority patent/DK3362445T3/da
Priority to RU2018117502A priority patent/RU2695133C1/ru
Priority to MYPI2018701042A priority patent/MY196174A/en
Priority to CA3001666A priority patent/CA3001666C/en
Priority to FIEP16855690.0T priority patent/FI3362445T3/fi
Priority to HRP20230201TT priority patent/HRP20230201T1/hr
Priority to BR112018007289-3A priority patent/BR112018007289B1/pt
Priority to MX2018004447A priority patent/MX384527B/es
Priority to NZ740809A priority patent/NZ740809A/en
Application filed by Chong Kun Dang Corp filed Critical Chong Kun Dang Corp
Priority to AU2016338118A priority patent/AU2016338118B2/en
Priority to EP16855690.0A priority patent/EP3362445B1/en
Priority to US15/763,972 priority patent/US10494355B2/en
Priority to CN201680072029.8A priority patent/CN108699048B/zh
Publication of WO2017065473A1 publication Critical patent/WO2017065473A1/en
Priority to PH12018500773A priority patent/PH12018500773A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C211/34—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton
    • C07C211/35—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton containing only non-condensed rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Definitions

  • the present disclosure relates to oxadiazole amine derivative compounds having histone deacetylase 6 (HDAC6) inhibitory activity, stereoisomers thereof, or pharmaceutically acceptable salts thereof; uses thereof for the preparation of therapeutic medicaments; methods of treating diseases using the same; pharmaceutical compositions comprising the same; and methods for preparing the same.
  • HDAC6 histone deacetylase 6
  • Post-translational modifications such as acetylation are very crucial regulatory modules at the heart of biological processes in the cells and are tightly regulated by a multitude of enzymes. Histones are the chief protein components of chromatin and act as spools around which DNA strands. Also, the balance of histone acetylation and deacetylation is a critical role in the regulation of gene expression.
  • Histone deacetylases are enzymes that remove acetyl groups from lysine residues on histone proteins of chromatin, and are known to be associated with gene silencing and induce cell cycle arrest, angiogenic inhibition, immune regulation, cell death, etc. (Hassig et al., Curr. Opin. Chem. Biol. 1997, 1, 300-308). In addition, it was reported that the inhibition of enzymatic function of HDACs induces the apoptosis of cancer cells in vivo by reducing the activity of cancer cell survival-associated factors and activating cancer cell apoptosis-associated factors (Warrell et al, J. Natl. Cancer Inst. 1998, 90, 1621-1625).
  • HDACs In humans, 18 HDACs have been identified and are subdivided into four classes based on their homology to yeast HDACs. Among them, 11 HDACs use zinc as a cofactor and can be divided into three groups: Class I (HDAC1, 2, 3 and 8), Class II (IIa: HDAC4, 5, 7 and 9; IIb: HDAC6 and 10), Class IV (HDAC 11). Additionally, 7 HDACs of Class III (SIRT 1-7) require NAD + instead of zinc as a cofactor (Bolden et al., Nat. Rev. Drug Discov. 2006, 5(9), 769-784).
  • HDAC inhibitors are in preclinical or clinical development, but to date, only non-selective HDAC inhibitors have been identified as anticancer agents, and only vorinostat (SAHA) and romidepsin (FK228) have been approved for the treatment of cutaneous T-cell lymphoma.
  • SAHA vorinostat
  • FK2228 romidepsin
  • non-selective HDAC inhibitors are known to cause side effects such as fatigue and nausea, generally at high doses (Piekarz et al., Pharmaceuticals 2010, 3, 2751-2767). Such side effects have been reported to be due to the inhibition of class I HDACs. Due to such side effects, the use of non-selective HDAC inhibitors in the development of drugs other than anticancer drugs has been limited (Witt et al., Cancer Letters, 2009, 277, 8-21).
  • selective HDAC inhibitors have potential to be developed as therapeutic agents effective for the treatment of various diseases (Matthias et al., Mol. Cell. Biol. 2008, 28, 1688-1701).
  • HDAC6 a member of Class IIb HDACs, is present mainly in the cytoplasm and is involved in the deacetylation of a number of non-histone substrates (HSP90, cortactin, etc.), including tubulin, (Yao et al., Mol. Cell 2005, 18, 601-607). HDAC6 has two catalytic domains, and the zinc finger domain of C-terminal can bind to ubiquitinated proteins.
  • HDAC6 has a number of non-histone proteins as substrates, and thus plays an important role in various diseases, including cancer, inflammatory diseases, autoimmune diseases, neurological diseases and neurodegenerative disorders (Santo et al., Blood 2012 119: 2579-258; Vishwakarma et al., International Immunopharmacology 2013, 16, 72-78; Hu et al., J. Neurol. Sci. 2011, 304, 1-8).
  • the common structural characteristic of various HDAC inhibitors is a structure consisting of a cap group, a linker and a zinc-binding group (ZBG), as shown in the following Vorinostat structure.
  • ZBG zinc-binding group
  • Many researchers have conducted studies on enzyme inhibitory activity and selectivity by structurally modifying the cap group and the linker.
  • the zinc-binding group is known to play a more important role in enzyme inhibitory activity and selectivity (Wiest et al., J. Org. Chem. 2013 78: 5051-5065; Methot et al., Bioorg. Med. Chem. Lett. 2008, 18, 973-978).
  • the zinc-binding group is generally a hydroxamic acid or benzamide derivative.
  • the hydroxamic acid derivative exhibits a potent HDAC inhibitory effect, but has problems of low bioavailability and severe off-target activity.
  • the benzamide derivative has a problem in that it can produce toxic metabolites in vivo , because it contains aniline (Woster et al., Med. Chem. Commun. 2015, online publication).
  • Another object of the present disclosure is to provide pharmaceutical compositions comprising oxadiazole amine derivative compounds having selective HDAC6 inhibitory activity, stereoisomers thereof, or pharmaceutically acceptable salts thereof.
  • Still another object of the present disclosure is to provide methods for preparing the novel compounds.
  • Still another object of the present disclosure is to provide pharmaceutical compositions for prevention or treatment of HDAC6 activity-associated diseases, including infectious diseases; neoplasms; endocrine, nutritional and metabolic diseases; mental and behavioral disorders; neurological diseases; diseases of the eye and adnexa; cardiovascular diseases; respiratory diseases; digestive diseases; diseases of the skin and subcutaneous tissue; diseases of the musculoskeletal system and connective tissue; or congenital malformations, deformations and chromosomal abnormalities, which contain the above compound.
  • infectious diseases including infectious diseases; neoplasms; endocrine, nutritional and metabolic diseases; mental and behavioral disorders; neurological diseases; diseases of the eye and adnexa; cardiovascular diseases; respiratory diseases; digestive diseases; diseases of the skin and subcutaneous tissue; diseases of the musculoskeletal system and connective tissue; or congenital malformations, deformations and chromosomal abnormalities, which contain the above compound.
  • Still another object of the present disclosure is to provide the use of the compounds for the preparation of therapeutic medicaments against HDAC6 activity-associated diseases.
  • Yet another object of the present disclosure is to provide methods for treating HDAC6 activity-associated diseases, which comprise administering a therapeutically effective amount of the pharmaceutical compositions containing the compounds.
  • HDAC6 histone deacetylase 6
  • -(C 1 -C 2 alkyl)- refers to -CH 2 - or -CH 2 CH 2 -.
  • -(C 1 -C 4 alkyl) or -(C 1 -C 6 alkyl) refers to a straight- or branched-chain C 1 -C 4 or C 1 -C 6 saturated hydrocarbon, for example, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, pentyl, or hexyl.
  • -(C 2 -C 4 alkenyl) refers to a straight- or branched-chain unsaturated hydrocarbon having at least one double bond, for example, ethenyl, propenyl or butenyl.
  • heterocycloalkyl refers to a saturated cyclic compound containing 1 to 3 heteroatoms selected from N, O and S as a ring member.
  • heteroaryl refers to an aromatic cyclic compound containing 1 to 3 heteroatoms selected from N, O and S as a ring member.
  • R 1 is -CF 2 H or -CF 3 ;
  • L 1 and L 2 are each independently -(C 1 -C 2 alkyl)- or null;
  • Z 1 to Z 4 are each independently N or CR Z ⁇ wherein three or more of Z 1 to Z 4 cannot be N at the same time ⁇ , wherein R Z is -H, -F, -Cl, -Br, -I or -O(C 1 -C 4 alkyl);
  • R 2 is -H or -(C 1 -C 4 alkyl);
  • a and b are each independently an integer of 0, 1, 2, 3 or 4 ⁇ wherein the a and b cannot all be 0 ⁇ ;
  • L 3 is -(C 1 -C 2 alkyl)-, -SO 2 -, -(C 1 -C 2 alkyl)-SO 2 -, or null;
  • Z 5 and Z 6 are each independently -CH 2 - or -O-;
  • R 1 is -CF 2 H or -CF 3 ;
  • L 1 and L 2 are null
  • Z 1 and Z 3 are N;
  • Z 2 and Z 4 are CR Z , wherein R Z is -H, -F, -Cl, -Br, -I or -O(C 1 -C 4 alkyl);
  • R 2 is -H or -(C 1 -C 4 alkyl);
  • a and b are each independently an integer of 0, 1, 2 or 3 ⁇ wherein the a and b cannot all be 0 ⁇ ;
  • L 3 is -(C 1 -C 2 alkyl)-, (C 1 -C 2 alkyl)-SO 2 -, or null;
  • phenyl is phenyl, pyridine, benzo[d][1,3]dioxol, thiophene, pyrimidine, pyrazine or pyridazine;
  • R 4 to R 6 are each independently -H, -F, -Cl, -Br, -I, -OH, -O(C 1 -C 4 alkyl), -(C 1 -C 4 alkyl), -CF 3 , -OCF 3 , piperidine, morpholino, piperazine or pyrrolidine ⁇ wherein the piperidine, morpholino, piperazine or pyrrolidine may be unsubstituted or substituted with C 1 -C 4 alkyl ⁇ , or wherein Y 2 is -O-, Y 3 and Y 5 are -CH-, Y 4 is -N-, c and e are each independently an integer of 0, 1 or 2 ⁇ wherein c and e cannot all be 0 ⁇ , and d and f are each independently an integer of 0, 1, 2 or 3 ⁇ wherein d and f cannot all be 0 ⁇ .
  • the oxadiazole amine derivative compound represented by the above Formula I may be a compound represented by the following Formula II:
  • R 1 is -CF 2 H or -CF 3 ;
  • R 2 is -H
  • a and b are each independently an integer of 0, 1, 2 or 3 ⁇ wherein a and b cannot all be 0, preferably, a ring formed by Y 1 , a and b is a 3- to 7-membered saturated cycloalkyl when Y 1 is-CH 2 -, or a ring formed by Y 1 , a and b is a 3- to 7-membered saturated heterocycloalkyl containing one N when Y1 is -NR c - ⁇ ;
  • L 3 is -(C 1 -C 2 alkyl)-, (C 1 -C 2 alkyl)-SO 2 -, or null;
  • R 4 to R 6 are each independently -H, -F, -Cl, -Br, -I, -OH, -O(C 1 -C 4 alkyl), -(C 1 -C 4 alkyl), -CF 3 , -OCF 3 , piperidine, morpholino ⁇ wherein the piperidine may be unsubstituted or substituted with C 1 -C 4 alkyl ⁇ , or
  • R 1 is -CF 2 H or -CF 3 ;
  • R 2 is -H
  • Y 1 is -CH 2 - or -NR c -, wherein R C is -H, or
  • a and b are each independently an integer of 0, 1, 2 or 3 ⁇ wherein the a and b cannot all be 0, and a ring formed by Y 1 , a and b is a 3- to 7-membered saturated cycloalkyl when Y 1 is-CH 2 - or a ring formed by Y 1 , a and b is a 3- to 7-membered saturated heterocycloalkyl containing one N when Y 1 is -NR c - ⁇ ;
  • L 3 is -CH 2 -, - CH 2 -SO 2 -, or null;
  • R 4 to R 6 are each independently -H, -F, -Cl, -Br, -I, -OH, -O(C 1 -C 4 alkyl), -(C 1 -C 4 alkyl), -CF 3 , -OCF 3 , morpholino, , or , wherein R 7 is -H or -(C 1 -C 4 alkyl).
  • the compound represented by formula I may be a compound represented by formula I-1:
  • R 1 is -CF 2 H or -CF 3 ;
  • R 2 is -H
  • Y 1 is -CH 2 -, -NH-, or
  • a and b are each independently an integer of 0, 1, 2 or 3 ⁇ wherein the a and b cannot all be 0, and a ring formed by Y 1 , a and b is a 3- to 7-membered saturated cycloalkyl when Y 1 is-CH 2 - or a ring formed by Y 1 , a and b is a 3- to 7-membered saturated heterocycloalkyl containing one N when Y 1 is -NR c - ⁇ ;
  • L 3 is -(C 1 -C 2 alkyl)-, -(C 1 -C 2 alkyl)-SO 2 -, or null;
  • R 4 to R 6 are each independently -H, -F, -Cl, -Br, -I, -OH, -O(C 1 -C 4 alkyl), -(C 1 -C 4 alkyl), -CF 3 , -OCF 3 , morpholino, piperidine ⁇ wherein the piperidine may be unsubstituted or substituted with C 1 -C 4 alkyl ⁇ , or .
  • the piperidine is or , and R 7 is -H or -(C 1 -C 4 alkyl).
  • the compound represented by formula I may be a compound represented by the following formula I-2:
  • R 1 is -CF 2 H or -CF 3 ;
  • R 2 is -H
  • a and b are each independently an integer of 0, 1, 2 or 3 ⁇ wherein the a and b cannot all be 0, and a ring formed by a and b is a 3- to 7-membered saturated cycloalkyl ⁇ ;
  • L 3 is -(C 1 -C 2 alkyl)-, -(C 1 -C 2 alkyl)-SO 2 -, or null;
  • X 1 and X 2 are each independently N or C ⁇ wherein both X 1 and X 2 cannot be N at the same time ⁇ .
  • the compound represented by formula I may be a compound represented by the following formula I-3:
  • R 1 is -CF 2 H or-CF 3 ;
  • R 2 is -H
  • a and b are each independently an integer of 0, 1, 2 or 3 ⁇ wherein the a and b cannot all be 0, and a ring formed by a and b is a 3- to 7-membered saturated cycloalkyl ⁇ ;
  • L 3 is -(C 1 -C 2 alkyl)-, -(C 1 -C 2 alkyl)-SO 2 -, or null;
  • X 3 and X 4 are each independently S or C ⁇ wherein X 3 and X 4 cannot be S or C at the same time ⁇ .
  • the compound represented by formula I may be a compound represented by the following formula I-4:
  • R 1 is -CF 2 H or-CF 3 ;
  • R 2 is -H
  • a and b are each independently an integer of 0, 1, 2 or 3 ⁇ wherein the a and b cannot all be 0, and a ring formed by a and b is a 3- to 7-membered saturated cycloalkyl ⁇ ;
  • L 3 is -(C 1 -C 2 alkyl)-, -(C 1 -C 2 alkyl)-SO 2 -, or null.
  • the compounds represented by formula I, stereoisomers thereof or pharmaceutically acceptable salts thereof may be selected from the group consisting of compounds 1524, 1559, 1579, 1603, 1605, 1607, 1609, 1611, 1614, 1615, 1616 and 1640. More preferably, the compounds represented by formula I, stereoisomers thereof or pharmaceutically acceptable salts thereof may be selected from the group consisting of compounds 1559, 1607, 1609, 1614, 1615 and 1640.
  • the term "pharmaceutically acceptable salt” means any salt that is generally used in the pharmaceutical field.
  • the pharmaceutically acceptable salt include, but are not limited to, salts with inorganic ions such as calcium, potassium, sodium or magnesium ions, salts with inorganic acids such as hydrochloric acid, nitric acid, phosphoric acid, bromic acid, iodic acid, perchloric acid or sulfuric acid, salts with organic acids such as acetic acid, trifluoroacetic acid, citric acid, maleic acid, succinic acid, oxalic acid, benzoic acid, tartaric acid, fumaric acid, mandelic acid, propionic acid, lactic acid, glycolic acid, gluconic acid, galacturonic acid, glutamic acid, glutaric acid, glucuronic acid, aspartic acid, ascorbic acid, carbonic acid, vanillic acid, hydroiodic acid or the like, salts with sulfonic acids such as methanesulfonic
  • preferred salts include salts with hydrochloric acid, phosphoric acid, sulfuric acid, trifluoroacetic acid, citric acid, bromic acid, maleic acid, tartaric acid or the like.
  • the compounds represented by formula I may contain one or more asymmetrical carbon atoms, and thus may exist in the form of racemates, racemic mixtures, single enantiomers, diastereomeric mixtures, and individual diastereomers.
  • the compounds of formula I can be separated into such isomers by methods known in the art, for example, column chromatography or HPLC.
  • stereoisomers of the compounds of formula I may be synthesized by stereospecific synthesis using optically pure starting materials and/or reagents of known configuration.
  • the present disclosure provides methods for the preparation of the oxadiazole amine derivative compounds presented by formula I, streoisomers thereof, or pharmaceutically acceptable salts thereof.
  • R 3 denotes .
  • Reaction scheme 1 shows a method for preparing an intermediate for preparation of the oxadiazole amine derivative compound represented by formula I, an optical isomer thereof, or a pharmaceutically acceptable salt thereof.
  • Reaction scheme 1 above shows a method for preparation of a compound having a primary amine structure.
  • compounds of formula 1-1-6 which have various structures, are prepared from the respective starting materials by the following three methods.
  • a compound of formula 1-1-1 is reacted with potassium cyanide to yield a compound of formula 1-1-2.
  • the compound of formula 1-1-2 is subjected to a substitution reaction with a compound of formula 1-1-3 to yield a compound of formula 1-1-4.
  • the nitrile of the compound of formula 1-1-4 is hydrolyzed to produce a compound of formula 1-1-5 having an amide structure, which is then subjected to a Hofmann rearrangement reaction, thereby preparing a compound of formula 1-1-6 having an amine structure.
  • Ellman's sulfinamide is added to a compound of formula 1-1-7 to yield an amine compound of formula 1-1-8, which is then reacted with a compound of formula 1-1-9, which is a nucleophile, thereby preparing a compound of formula 1-1-10.
  • the compound of formula 1-1-10 is treated with hydrochloric acid to remove the alkylsulfinyl (e.g., butylsulfinyl), thereby preparing an ammonium salt compound of formula 1-1-6 having an amine structure.
  • Reaction scheme 2 above shows a method for synthesis of a compound having a 1,3,4-oxadiazole structure.
  • the compound of formula 1-1-6 prepared according to reaction scheme 1 above, is subjected to a substitution reaction with a compound of formula 1-2-1 to yield a compound of formula 1-2-2.
  • the ester moiety of the compound of formula 1-2-2 is substituted with hydrazine, and then reacted with trifluoroacetic acid anhydride or difluoroacetic acid anhydride to thereby prepare a compound of formula 1-2-5.
  • compounds which are prepared according to the above reaction scheme include compounds 1524, 1526, 1559, 1579, 1580, 1581, 1582, 1603, 1604, 1605, 1606, 1607, 1608, 1609, 1610, 1611, 1612, 1614, 1615, 1616, 1617, 1618, 1640, 1641, 1642, 1670, 1671, 1672, 1673, 1674, 1675, 1676, 1711, 1712, 1713, 1714, 1722, 1723, 1738, 1740, 1741, 1742, 1761, 1779, 1780, 1817, 1818, 1819, 1820, 1821, 1822, 1826, 1827, 1828, 1832, 1833, 1834, 1835, 1836, 1837, 1838, 1913, 1959, 1960, 1961, 1962, 1963, 1964, 1965, 1966, 2026, 2027, 2028, 2030, 2033, 2034, 2038, 2040, 2042, 2043, 2044, 2045, 2047, 2048
  • Reaction scheme 3 above shows a method for synthesis of a 1,3,4-oxadiazole compound having a heterocycloalkyl structure.
  • a protecting group is added to an amine of formula 1-3-1 to yield a compound of formula 1-3-2.
  • the compound of formula 1-3-2 is subjected to a substitution reaction with a compound of formula 1-1-2 to yield a compound of formula 1-3-3, and the nitrile of the compound of formula 1-3-3 is hydrolyzed to yield a compound of formula 1-3-4 having an amide structure, which is then subjected to a Hofmann rearrangement reaction, thereby preparing a compound of formula 1-3-5 having an amine structure.
  • the compound of formula 1-3-5 is subjected to a substitution reaction with a compound of formula 1-2-1 to yield a compound of formula 1-3-6, and the ester moiety of formula 1-3-6 is substituted with hydrazine, and then reacted with trifluoroacetic acid anhydride or difluoroacetic acid anhydride to yield a compound of formula 1-3-8.
  • the compound of formula 1-3-8 is reacted with 1-methoxy-N-(triethylammoniosulfonyl)-methaneimidate (Burgess reagent) to yield a compound of formula 1-3-9 (for example, compound 1677), which has a 1,3,4-oxadiazole structure.
  • the protecting group is removed, thereby preparing a compound of formula 1-3-10 (for example, compound 1678).
  • Reaction scheme 4 above shows a method for synthesis of a compound having a 1,3,4-oxadiazole structure. As shown therein, a compound of formula 1-4-1 is hydrolyzed to yield a compound of formula 1-4-2, which is then subjected to an amide coupling reaction to yield a compound of formula 1-4-3.
  • the compound of formula 1-4-3 is reacted with trifluoroacetic acid anhydride or difluoroacetic acid anhydride to yield a compound of formula 1-4-4, which is then reacted with 1-methoxy-N-(triethylammoniosulfonyl)-methaneimidate (Burgess reagent), thereby preparing a compound of formula 1-4-5, which has a 1,3,4-oxadiazole structure.
  • the compound of formula 1-4-5 is subjected to an oxidation reaction to yield a compound of formula 1-4-6, which is then subjected to a substitution reaction with a compound of formula 1-1-6, thereby preparing a compound of formula 1-4-7 (for example, compound 1683).
  • Reaction scheme 5 above shows a method for synthesis of a compound which includes a heterocyclic amine derivative and which has a 1,3,4-oxadiazole structure.
  • a protecting group is added to an amine of formula 1-1-6 to yield a compound of formula 1-5-1.
  • the compound of formula 1-5-1 is subjected to a C-N coupling reaction (Buchwald reaction) with a compound of formula 1-5-2, which is a heterocyclic amine derivative, thereby preparing a compound of formula 1-5-3.
  • the protecting group is removed to yield a compound of formula 1-5-4.
  • the compound of formula 1-5-4 is subjected to a C-N coupling reaction (Buchwald reaction) with a compound of formula 1-5-2 to yield a compound of formula 1-5-5. Then, the nitrile of the compound of formula 1-5-5 is hydrolyzed to yield a compound of formula 1-5-6 having an amide structure, which is then subjected to a Hofmann rearrangement reaction, thereby preparing a compound of formula 1-5-4.
  • a C-N coupling reaction Buchwald reaction
  • the nitrile of the compound of formula 1-5-5 is hydrolyzed to yield a compound of formula 1-5-6 having an amide structure, which is then subjected to a Hofmann rearrangement reaction, thereby preparing a compound of formula 1-5-4.
  • the compound of formula 1-5-4 is subjected to a substitution reaction with a compound of formula 1-2-1 to yield a compound of formula 1-5-7.
  • the ester moiety of the compound of formula 1-5-7 is substituted with hydrazine, and then reacted with trifluoroacetic acid anhydride or difluoroacetic acid anhydride to yield a compound of formula 1-5-9, which is then reacted with 1-methoxy-N-(triethylammoniosulfonyl)-methaneimidate (Burgess reagent), thereby preparing a compound of formula 1-5-10, which includes a heterocyclic amine derivative and has a 1,3,4-oxadiazole structure.
  • compounds which are prepared according to the above reaction scheme include compounds 2041, 2062 and 2046.
  • Reaction scheme 6 above shows a method for synthesis of a compound which includes a heterocyclic amine derivative and which has a 1,3,4-oxadiazole structure.
  • an amine of formula 1-2-2 is subjected to a C-C coupling reaction (Suzuki reaction) with a protected compound of formula 1-6-1 to yield a compound of formula 1-6-2.
  • the compound of formula 1-6-2 is hydrogenated to yield a compound of formula 1-6-3, which is then subjected to reductive amination and substitution reactions to thereby prepare a compound of formula 1-6-4.
  • ester moiety of the compound of formula 1-6-4 is substituted with hydrazine, and then reacted with trifluoroacetic acid anhydride or difluoroacetic acid anhydride to yield a compound of formula 1-6-6, which is then reacted with 1-methoxy-N-(triethylammoniosulfonyl)-methaneimidate (Burgess reagent) to thereby prepare a compound of formula 1-6-7, which includes a heterocyclic amine derivative and has a 1,3,4-oxadiazole structure.
  • R is either of the substituent group defined as in formula I, or -(C1-C4 alkyl).
  • compounds which are prepared according to the above reaction scheme include compounds 2023, 2035, 2036, 2037 and 2060.
  • compositions comprising oxadiazole amine derivative compounds, the use thereof and the method of treating diseases
  • the present disclosure provides a pharmaceutical composition
  • a pharmaceutical composition comprising a compound represented by the following formula I, a stereoisomer thereof or a pharmaceutically acceptable salt thereof:
  • the present disclosure provides a pharmaceutical composition for preventing or treating histone deacetylase 6 (HDAC6) activity-associated diseases comprising a compound represented by the following formula I, a stereoisomer thereof or a pharmaceutically acceptable salt thereof:
  • the pharmaceutical composition according to the present disclosure exhibits a remarkable effect on the prevention or treatment of histone deacetylase 6 (HDAC6) activity-associated diseases by selectively inhibiting histone deacetylase 6 (HDAC6).
  • HDAC6 histone deacetylase 6
  • the histone deacetylase 6 (HDAC6) activity-associated diseases include infectious diseases such as prion disease; neoplasms such as benign tumor(e.g. myelodysplastic syndrome) or malignant tumor(e.g. multiple myeloma, lymphoma, leukemia, lung cancer, rectal cancer, colon cancer, prostate cancer, urothelial carcinoma, breast cancer, melanoma, skin cancer, liver cancer, brain cancer, gastric cancer, ovarian cancer, pancreatic cancer, head and neck cancer, oral cancer, or glioma); endocrine, nutritional and metabolic diseases such as Wilson's disease, amyloidosis or diabetes; mental and behavioral disorders such as depression or Rett's syndrome, and the like; neurological diseases such as atrophy of central nervous system (e.g.
  • Huntington's disease spinal muscular atrophy (SMA), spinocerebellar ataxia (SCA)), neurodegenerative disease (e.g. Alzheimer's disease), movement disorder (e.g. Parkinson's disease), neuropathy (e.g. hereditary neuropathy (Charcot-Marie-Tooth disease), sporadic neuropathy, inflammatory neuropathy, drug-induced neuropathy), motor neuron diseases (amyotrophic lateral sclerosis (ALS)), or demyelinating diseases of the central nervous system (e.g.
  • MS multiple sclerosis
  • diseases of the eye and adnexa such as uveitis
  • cardiovascular diseases such as atrial fibrillation or stroke and the like
  • respiratory diseases such as asthma
  • digestive diseases such as alcoholic liver disease, inflammatory bowel disease, Crohn's disease or ulcerative bowel disease, and the like
  • diseases of the skin and subcutaneous tissue such as psoriasis
  • diseases of the musculoskeletal system and connective tissue such as rheumatoid arthritis, osteoarthritis or systemic lupus erythematosus (SLE), and the like
  • congenital malformations, deformations and chromosomal abnormalities such as autosomal dominant polycystic kidney disease, as well as disorders or diseases associated with the abnormal function of histone deacetylase.
  • the pharmaceutically acceptable salt is as described above with respect to a pharmaceutically acceptable salt of the compound represented by formula I according to the present disclosure.
  • the pharmaceutical composition according to the present disclosure may further contain at least one pharmaceutically acceptable carrier in addition to the compound of formula I, an isomer thereof or a pharmaceutically acceptable salt thereof.
  • the pharmaceutically acceptable carrier that is used in the present disclosure may be at least one of physiological saline, sterile water, Ringer solution, buffered saline, dextrose solution, maltodextrin solution, glycerol, ethanol, and a mixture of two or more thereof. If necessary, the composition may contain other conventional additives such as an antioxidant, a buffer or a bacteriostatic agent.
  • compositions can be formulated into injectable formulations such as solutions, suspensions, turbid fluid, etc, pills, capsules, granules or tablets using a diluent, a dispersing agent, a surfactant, a binder and a lubricant.
  • injectable formulations such as solutions, suspensions, turbid fluid, etc, pills, capsules, granules or tablets using a diluent, a dispersing agent, a surfactant, a binder and a lubricant.
  • the composition of the present disclosure may be in the form of patches, liquids, pills, capsules, granules, tablets, suppositories, etc.
  • These formulations can be prepared either by conventional methods that are used for formulation in the art or by the method disclosed in Remington's Pharmaceutical Science (the latest edition), Mack Publishing Company, Easton PA.
  • the pharmaceutical composition of the present disclosure may be administered orally or parenterally (e.g., intravenously, subcutaneously, intraperitoneally or topically) depending on the intended use.
  • the dose of the pharmaceutical composition varies depending on the patient's weight, age, sex, health conditions and diet, the time of administration, the mode of administration, excretion rate, the severity of the disease, and the like.
  • the daily dose of the compound of formula I according to the present disclosure may be about 1 to 1000 mg/kg, preferably 5 to 100 mg/kg, and may be administered once to several times a day.
  • composition of the present disclosure may further contain, in addition to the compound represented by formula I, a stereoisomer thereof or a pharmaceutically acceptable salt thereof, one or more active ingredients that exhibit medicinal efficacy identical or similar thereto.
  • the present disclosure also provides a method for preventing or treating a histone deacetylase-mediated disease, which comprises administering a therapeutically effective amount of the compound represented by formula I, a stereoisomer thereof or a pharmaceutically acceptable salt thereof.
  • terapéuticaally effective amount refers to the amount of the compound represented by formula I, which is effective for the prevention or treatment of histone deacetylase 6 activity-associated diseases.
  • the present disclosure also provides a method of selectively inhibiting HDAC6, which comprises administering the compound of formula I, a stereoisomer thereof or a pharmaceutically acceptable salt thereof to mammals including humans.
  • the method of preventing or treating histone deacetylase 6 activity-associated disease includes inhibiting or averting the disease as well as addressing the disease itself, prior to the onset of symptoms by administering the compound represented by formula I.
  • the magnitude of a prophylactic or therapeutic dose of a particular active ingredient will vary with the nature and severity of the disease or condition, and may also vary according to the route by which the active ingredient is administered.
  • the dose and the dose frequency will also vary according to the age, body weight, and response of the individual patient. Suitable dosing regimens can be readily selected by those skilled in the art with due consideration of such factors.
  • the method of preventing or treating histone deacetylase 6 activity-associated disease may further comprise administering a therapeutically effective amount of an additional active agent helpful for the treatment of the disease together with the compound represented by formula I, in which the additional active agent can exhibit a synergistic effect with the compound of formula I or an assistant effect.
  • the present disclosure is also intended to provide the use of the compound represented by formula I, a stereoisomer thereof or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for treating histone deacetylase 6 activity-associated disease.
  • the compound represented by formula I may be mixed with a pharmaceutically acceptable adjuvant, diluent, carrier or the like, and combined with other active agents such that the active ingredients can have synergistic effects.
  • composition and treatment method of the present disclosure may be appropriately combined unless contradictory to one another.
  • the compounds represented by formula I, stereoisomers thereof or pharmaceutically acceptable salts thereof can selectively inhibit HDAC6, and thus exhibit excellent effects on the prevention or treatment of histone deacetylase 6 activity-associated diseases.
  • Example 1 Compound 1524, 5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-N-(1-phenylcyclopropyl)pyrimidin-2-amine
  • the reaction mixture was concentrated under the reduced pressure to remove the solvent. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The bi-phasic mixture was passed through a plastic frit to remove the solid residues and aqueous layer, and the organic layer collected was concentrated in vacuo.
  • Example 2 Compound 1526, N-(1-phenylcyclopropyl)-5-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)pyrimidin-2-amine
  • the bi-phasic mixture was passed through a plastic frit to remove the solid residues and aqueous layer, and the organic layer collected was concentrated in vacuo.
  • Example 3 Compound 1559, 5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-N-(1-phenylcyclobutyl)pyrimidin-2-amine
  • N'-(2,2-difluoroacetyl)-2-((1-phenylcyclobutyl)amino)pyrimidine-5-carbohydrazide (0.128 g, 0.354 mmol) and 1-methoxy-N-triethylammoniosulfonyl-methanimidate (Burgess reagent, 0.127 g, 0.531 mmol) in tetrahydrofuran (4 mL) was mixed at the room temperature, heated at 150 °C under the microwaves for 30 min, and cooled down to the room temperature to terminate reaction. The reaction mixture was concentrated under the reduced pressure to remove the solvent. Then, water was added to the reaction mixture, followed by extraction with dichloromethane.
  • the bi-phasic mixture was passed through a plastic frit to remove the solid residues and aqueous layer, and the organic layer collected was concentrated in vacuo.
  • Example 4 Compound 1579, 5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-N-(1-phenylcyclopentyl)pyrimidin-2-amine
  • the concentrate was diluted with ethyl acetate and hydrochloric acid (4.00 M solution, 2.718 mL, 10.872 mmol) and stirred at the ambient temperature.
  • 1-phenylcyclopentan-1-amine hydrochloride were collected by filtration and dried to give 1-phenylcyclopentan-1-amine hydrochloride as white solid (0.753 g, 53.4 %).
  • 1-phenylcyclopentan-1-amine hydrochloride (0.753 g, 3.809 mmol), ethyl 2-chloropyrimidine-5-carboxylate (0.746 g, 3.999 mmol) and N,N-diisopropylethylamine (3.317 mL, 19.043 mmol) were mixed at the room temperature in 1,4-dioxane (10 mL), stirred at 90 °C for 17 hr, and cooled down to the room temperature to terminate the reaction. Ssturated water was added to the reaction mixture, followed by extraction with ethyl acetate.
  • N'-(2,2-difluoroacetyl)-2-((1-phenylcyclopentyl)amino)pyrimidine-5-carbohydrazide (0.192 g, 0.511 mmol) and 1-methoxy-N-triethylammoniosulfonyl-methanimidate (Burgess reagent, 0.183 g, 0.767 mmol) in tetrahydrofuran (4 mL) was mixed at the room temperature, heated at 150 °C under the microwaves for 30 min, and cooled down to the room temperature to terminate reaction. The reaction mixture was concentrated under the reduced pressure to remove the solvent. Then, water was added to the reaction mixture, followed by extraction with dichloromethane.
  • the bi-phasic mixture was passed through a plastic frit to remove the solid residues and aqueous layer, and the organic layer collected was concentrated in vacuo.
  • Example 5 Compound 1580, N-(1-phenylcyclopentyl)-5-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)pyrimidin-2-amine
  • the bi-phasic mixture was passed through a plastic frit to remove the solid residues and aqueous layer, and the organic layer collected was concentrated in vacuo.
  • Example 6 Compound 1581, 5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-N-(1-phenylcyclohexyl)pyrimidin-2-amine
  • the concentrate was diluted with ethyl acetate and hydrochloric acid (4.00 M solution, 2.011 mL, 8.043 mmol) and stirred at the ambient temperature.
  • the resulting precipitates were collected by filtration, washed by ethyl acetate and dried to give 1-phenylcyclohexan-1-amine hydrochloride as white solid (0.536 g, 47.2 %).
  • the bi-phasic mixture was passed through a plastic frit to remove the solid residues and aqueous layer, and the organic layer collected was concentrated in vacuo.
  • N'-(2,2-difluoroacetyl)-2-((1-phenylcyclohexyl)amino)pyrimidine-5-carbohydrazide (0.215 g, 0.552 mmol) and 1-methoxy-N-triethylammoniosulfonyl-methanimidate (Burgess reagent, 0.197 g, 0.828 mmol) in tetrahydrofuran (4 mL) was mixed at the room temperature and then heated at 150 °C under the microwaves for 30 min, and cooled down to the room temperature to terminate reaction. The reaction mixture was concentrated under the reduced pressure to remove the solvent. Then, water was added to the reaction mixture, followed by extraction with dichloromethane.
  • the bi-phasic mixture was passed through a plastic frit to remove the solid residues and aqueous layer, and the organic layer collected was concentrated in vacuo.
  • Example 7 Compound 1582, N-(1-phenylcyclohexyl)-5-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)pyrimidin-2-amine
  • the bi-phasic mixture was passed through a plastic frit to remove the solid residues and aqueous layer, and the organic layer collected was concentrated in vacuo.
  • the bi-phasic mixture was passed through a plastic frit to remove the solid residues and aqueous layer, and the organic layer collected was concentrated in vacuo.
  • Example 8 Compound 1603, 5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-N-(1-(4-methoxyphenyl)cyclobutyl)pyrimidin-2-amine
  • 1-(4-methoxyphenyl)cyclobutan-1-amine hydrochloride 0.546 g, 2.555 mmol
  • ethyl 2-chloropyrimidine-5-carboxylate (0.501 g, 2.683 mmol
  • N,N-diisopropylethylamine 2.225 mL, 12.774 mmol
  • the reaction mixture was concentrated under the reduced pressure to remove the solvent.
  • the bi-phasic mixture was passed through a plastic frit to remove the solid residues and aqueous layer, and the organic layer collected was concentrated in vacuo.
  • N'-(2,2-difluoroacetyl)-2-((1-(4-methoxyphenyl)cyclobutyl)amino)pyrimidine-5-carbohydrazide 0.040 g, 0.102 mmol
  • 1-methoxy-N-triethylammoniosulfonyl-methanimidate Burgess reagent, 0.037 g, 0.153 mmol
  • tetrahydrofuran 3 mL
  • Example 9 Compound 1604, N-(1-(4-methoxyphenyl)cyclobutyl)-5-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)pyrimidin-2-amine
  • the bi-phasic mixture was passed through a plastic frit to remove the solid residues and aqueous layer, and the organic layer collected was concentrated in vacuo.
  • Example 10 Compound 1605, 5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-N-(1-(3-methoxyphenyl)cyclobutyl)pyrimidin-2-amine
  • the concentrate was diluted with ethyl acetate and hydrochloric acid (4.00 M solution in 1,4-dioxane, 3.599 mL, 14.396 mmol) and stirred at the ambient temperature.
  • the resulting precipitates were collected by filtration, washed by ethyl acetate and dried to give 1-(3-methoxyphenyl)cyclobutan-1-amine hydrochloride as white solid (1.070 g, 52.2 %).
  • 1-(3-methoxyphenyl)cyclobutan-1-amine hydrochloride (1.070 g, 5.007 mmol), ethyl 2-chloropyrimidine-5-carboxylate (0.981 g, 5.257 mmol) and N,N-diisopropylethylamine (4.360 mL, 25.034 mmol) were mixed at the room temperature in 1,4-dioxane (10 mL), stirred at 110 °C for 17 hr, and then cooled down to the room temperature to terminate the reaction. The reaction mixture was concentrated under the reduced pressure to remove the solvent.
  • the bi-phasic mixture was passed through a plastic frit to remove the solid residues and aqueous layer, and the organic layer collected was concentrated in vacuo.
  • N'-(2,2-difluoroacetyl)-2-((1-(3-methoxyphenyl)cyclobutyl)amino)pyrimidine-5-carbohydrazide (0.100 g, 0.256 mmol) and hydrochloric acid (0.010 g, 0.268 mmol) in tetrahydrofuran (3 mL) was mixed at the room temperature, heated at 150 °C under the microwaves for 30 min, and cooled down to the room temperature to terminate reaction. The reaction mixture was concentrated under the reduced pressure to remove the solvent. Then, water was added to the reaction mixture, followed by extraction with dichloromethane.
  • the bi-phasic mixture was passed through a plastic frit to remove the solid residues and aqueous layer, and the organic layer collected was concentrated in vacuo.
  • Example 11 Compound 1606, N-(1-(3-methoxyphenyl)cyclobutyl)-5-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)pyrimidin-2-amine
  • the bi-phasic mixture was passed through a plastic frit to remove the solid residues and aqueous layer, and the organic layer collected was concentrated in vacuo.
  • Example 12 Compound 1607, 5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-N-(1-(3-fluorophenyl)cyclobutyl)pyrimidin-2-amine
  • the concentrate was diluted with ethyl acetate and hydrochloric acid (4.00 M solution in 1,4-dioxane, 8.151 mL, 32.605 mmol) and stirred at the ambient temperature.
  • the resulting precipitates were collected by filtration, washed by ethyl acetate and dried to give 1-(3-fluorophenyl)cyclobutan-1-amine hydrochloride as white solid (2.390 g, 54.5 %).
  • 1-(3-fluorophenyl)cyclobutan-1-amine hydrochloride (0.609 g, 3.020 mmol), ethyl 2-chloropyrimidine-5-carboxylate (0.592 g, 3.171 mmol) and N,N-diisopropylethylamine (2.630 mL, 15.099 mmol) were mixed at the room temperature in 1,4-dioxane (10 mL), stirred at 110 °C for 17 hr, and cooled down to the room temperature to terminate the reaction. The reaction mixture was concentrated under the reduced pressure to remove the solvent.
  • N'-(2,2-difluoroacetyl)-2-((1-(3-fluorophenyl)cyclobutyl)amino)pyrimidine-5-carbohydrazide 0.112 g, 0.295 mmol
  • 1-methoxy-N-triethylammoniosulfonyl-methanimidate Burgess reagent, 0.106 g, 0.443 mmol
  • tetrahydrofuran 3 mL
  • Example 13 Compound 1608, N-(1-(3-fluorophenyl)cyclobutyl)-5-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)pyrimidin-2-amine
  • the bi-phasic mixture was passed through a plastic frit to remove the solid residues and aqueous layer, and the organic layer collected was concentrated in vacuo.
  • Example 14 Compound 1609, 5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-N-(1-(2-fluorophenyl)cyclobutyl)pyrimidin-2-amine
  • the concentrate was diluted with ethyl acetate and hydrochloric acid (4.00 M solution in 1,4-dioxane, 3.416 mL, 13.663 mmol) and stirred at the ambient temperature.
  • the resulting precipitates were collected by filtration , washed by ethyl acetate and dried to give 1-(2-fluorophenyl)cyclobutan-1-amine hydrochloride as white solid (0.609 g, 33.2 %).
  • 1-(2-fluorophenyl)cyclobutan-1-amine hydrochloride (0.609 g, 3.020 mmol), ethyl 2-chloropyrimidine-5-carboxylate (0.592 g, 3.171 mmol) and N,N-diisopropylethylamine (2.630 mL, 15.099 mmol) were mixed at the room temperature in 1,4-dioxane (10 mL), stirred at 110 °C for 17 hr, and then cooled down to the room temperature to terminate the reaction. The reaction mixture was concentratedunder the reduced pressure to remove the solvent.
  • the bi-phasic mixture was passed through a plastic frit to remove the solid residues and aqueous layer, and the organic layer collected was concentrated in vacuo.
  • N'-(2,2-difluoroacetyl)-2-((1-(2-fluorophenyl)cyclobutyl)amino)pyrimidine-5-carbohydrazide 0.062 g, 0.163 mmol
  • 1-methoxy-N-triethylammoniosulfonyl-methanimidate Burgess reagent, 0.058 g, 0.245 mmol
  • tetrahydrofuran 3 mL
  • Example 15 Compound 1610, N-(1-(2-fluorophenyl)cyclobutyl)-5-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)pyrimidin-2-amine
  • the bi-phasic mixture was passed through a plastic frit to remove the solid residues and aqueous layer, and the organic layer collected was concentrated in vacuo.
  • Example 16 Compound 1611, 5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-N-(1-(4-fluorophenyl)cyclobutyl)pyrimidin-2-amine
  • 1-(4-fluorophenyl)cyclobutan-1-amine hydrochloride 1.000 g, 4.959 mmol
  • ethyl 2-chloroopyrimidine-5-carboxylate 0.72 g, 5.207 mmol
  • N,N-diisopropylethylamine 1.296 mL, 7.438 mmol
  • N'-(2,2-difluoroacetyl)-2-((1-(4-fluorophenyl)cyclobutyl)amino)pyrimidine-5-carbohydrazide 0.226 g, 0.596 mmol
  • 1-methoxy-N-triethylammoniosulfonyl-methanimidate Burgess reagent, 0.213 g, 0.894 mmol
  • tetrahydrofuran 4 mL
  • Example 17 Compound 1612, N-(1-(4-fluorophenyl)cyclobutyl)-5-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)pyrimidin-2-amine
  • Example 18 Compound 1614, N-(1-(2-chlorophenyl)cyclobutyl)-5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyrimidin-2-amine
  • the concentrate was diluted with dichloromethane and then was added hydrochloric acid (4.00 M solution in Dioxane, 3.458 mL, 13.831 mmol) and stirred at the ambient temperature.
  • hydrochloric acid (4.00 M solution in Dioxane, 3.458 mL, 13.831 mmol) and stirred at the ambient temperature.
  • the resulting precipitates were collected by filtration, washed by diethylether, and dried to give 1-(2-chlorophenyl)cyclobutan-1-amine as White solid (0.800 g, 63.7 %).
  • Example 19 Compound 1615, N-(1-(3-chlorophenyl)cyclobutyl)-5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyrimidin-2-amine
  • the concentrate was diluted with dichloromethane (20 mL) and then was added hydrochloric acid (4.00 M solution in Dioxane, 5.723 mL, 22.893 mmol) and stirred at the ambient temperature.
  • hydrochloric acid (4.00 M solution in Dioxane, 5.723 mL, 22.893 mmol) and stirred at the ambient temperature.
  • the resulting precipitates were collected by filtration, washed by diethyl ether, and dried to give 1-(3-chlorophenyl)cyclobutan-1-amine hydrochloride as White solid (1.200 g, 57.7 %).
  • Example 20 Compound 1616, N-(1-(4-chlorophenyl)cyclobutyl)-5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyrimidin-2-amine
  • Example 21 Compound 1617, N-(1-(2-chlorophenyl)cyclobutyl)-5-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)pyrimidin-2-amine
  • Example 22 Compound 1618, N-(1-(4-chlorophenyl)cyclobutyl)-5-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)pyrimidin-2-amine
  • Example 23 Compound 1640, 5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-N-(1-(pyridin-2-yl)cyclobutyl)pyrimidin-2-amine
  • the concentrate was diluted with ethyl acetate and hydrochloric acid (4.00 M solution in 1,4-dioxane, 0.817 mL, 3.269 mmol) and stirred at the ambient temperature.
  • the resulting precipitates were collected by filtration and dried to give 1-(pyridin-2-yl)cyclobutan-1-amine hydrochloride as white solid (0.240 g, 59.6 %).
  • 1-(pyridin-2-yl)cyclobutan-1-amine hydrochloride (0.240 g, 1.300 mmol), ethyl 2-chloropyrimidine-5-carboxylate (0.252 g, 1.365 mmol) and N,N-diisopropylethylamine (0.679 mL, 3.899 mmol) were mixed at the room temperature in 1,4-dioxane (4 mL), stirred at 110 °C for 17 hr, and cooled down to the room temperature to terminate the reaction. The reaction mixture was concentrated under the reduced pressure to remove the solvent.
  • the bi-phasic mixture was passed through a plastic frit to remove the solid residues and aqueous layer, and the organic layer collected was concentrated in vacuo.
  • N'-(2,2-difluoroacetyl)-2-((1-(pyridin-2-yl)cyclobutyl)amino)pyrimidine-5-carbohydrazide 0.051 g, 0.141 mmol
  • 1-methoxy-N-triethylammoniosulfonyl-methanimidate Burgess reagent, 0.067 g, 0.282 mmol
  • tetrahydrofuran 3 mL
  • Example 24 Compound 1641, N-(1-(pyridin-2-yl)cyclobutyl)-5-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)pyrimidin-2-amine
  • the bi-phasic mixture was passed through a plastic frit to remove the solid residues and aqueous layer, and the organic layer collected was concentrated in vacuo.
  • Example 25 Compound 1642, 5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-N-(1-(3-(trifluoromethyl)phenyl)cyclobutyl)pyrimidin-2-amine
  • the bi-phasic mixture was passed through a plastic frit to remove the solid residues and aqueous layer, and the organic layer collected was concentrated in vacuo.
  • N'-(2,2-difluoroacetyl)-2-((1-(3-(trifluoromethyl)phenyl)cyclobutyl)amino)pyrimidine-5-carbohydrazide 0.060 g, 0.140 mmol
  • 1-methoxy-N-triethylammoniosulfonyl-methanimidate 0.050 g, 0.210 mmol
  • tetrahydrofuran 3 mL
  • Example 26 Compound 1670, 5-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)-N-(1-(3-(trifluoromethyl)phenyl)cyclobutyl)pyrimidin-2-amine
  • the concentrate was diluted with ethyl acetate and hydrochloric acid (4.00 M solution in 1,4-dioxane, 1.542 mL, 6.167 mmol) and stirred at the ambient temperature.
  • the resulting precipitates were collected by filtration, washed by ethyl acetate and dried to give 1-(3-(trifluoromethyl)phenyl)cyclobutan-1-amine hydrochloride as white solid (0.519 g, 50.2 %).
  • Example 27 Compound 1671, 5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-N-(1-(o-tolyl)cyclobutyl)pyrimidin-2-amine
  • the concentrate was diluted with ethyl acetate and hydrochloric acid (4.00 M solution in 1,4-dioxane, 3.091 mL, 12.364 mmol) and stirred at the ambient temperature.
  • the resulting precipitates were collected by filtration, washed by ethyl acetate and dried to give 1-(o-tolyl)cyclobutan-1-amine hydrochloride as white solid (1.200 g, 73.6 %).
  • 1-(o-tolyl)cyclobutan-1-amine hydrochloride (0.600 g, 3.035 mmol), ethyl 2-chloropyrimidine-5-carboxylate (0.595 g, 3.186 mmol) and N,N-diisopropylethylamine (1.586 mL, 9.104 mmol) were mixed at the room temperature in 1,4-dioxane (4 mL) and then stirred at 110 °C for 17 hr, and cooled down to the room temperature to terminate the reaction. The reaction mixture was concentrated under the reduced pressure to remove the solvent.
  • N'-(2,2-difluoroacetyl)-2-((1-(o-tolyl)cyclobutyl)amino)pyrimidine-5-carbohydrazide was used without further purification (0.155 g, 100.6 %, pale yellow solid).
  • N'-(2,2-difluoroacetyl)-2-((1-(o-tolyl)cyclobutyl)amino)pyrimidine-5-carbohydrazide (0.155 g, 0.413 mmol) and 1-methoxy-N-triethylammoniosulfonyl-methanimidate (Burgess reagent, 0.148 g, 0.619 mmol) in tetrahydrofuran (5 mL) was mixed at the room temperature, heated at 150 °C under the microwaves for 30 min, and cooled down to the room temperature to terminate reaction. The reaction mixture was concentrated under the reduced pressure to remove the solvent.
  • Example 28 Compound 1672, N-(1-(o-tolyl)cyclobutyl)-5-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)pyrimidin-2-amine
  • Example 29 Compound 1673, 5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-N-(1-(m-tolyl)cyclobutyl)pyrimidin-2-amine
  • the concentrate was diluted with ethyl acetate and hydrochloric acid (4.00 M solution in 1,4-dioxane, 1.981 mL, 7.926 mmol) and stirred at the ambient temperature.
  • the resulting precipitates were collected by filtration and dried to give 1-(m-tolyl)cyclobutan-1-amine hydrochloride as white solid (0.800 g, 76.6 %).
  • 1-(m-tolyl)cyclobutan-1-amine hydrochloride (0.400 g, 2.023 mmol), ethyl 2-chloropyrimidine-5-carboxylate (0.396 g, 2.124 mmol) and N,N-diisopropylethylamine (1.057 mL, 6.069 mmol) were mixed at the room temperature in 1,4-dioxane (4 mL), stirred at 110 °C for 17 hr, and cooled down to the room temperature to terminate the reaction. The reaction mixture was concentrated under the reduced pressure to remove the solvent.
  • N'-(2,2-difluoroacetyl)-2-((1-(m-tolyl)cyclobutyl)amino)pyrimidine-5-carbohydrazide (0.180 g, 0.480 mmol) and 1-methoxy-N-triethylammoniosulfonyl-methanimidate (Burgess reagent, 0.171 g, 0.719 mmol) in tetrahydrofuran (5 mL) was mixed at the room temperature, heated at 150 °C under the microwaves for 30 min, and cooled down to the room temperature to terminate reaction. The reaction mixture was concentrated under the reduced pressure to remove the solvent.
  • Example 30 Compound 1674, N-(1-(m-tolyl)cyclobutyl)-5-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)pyrimidin-2-amine
  • Example 31 Compound 1675, 5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-N-(1-(p-tolyl)cyclobutyl)pyrimidin-2-amine
  • the concentrate was diluted with ethyl acetate and was added hydrochloric acid (4.00 M solution in 1,4-dioxane, 5.845 mL, 23.381 mmol) and stirred at the ambient temperature.
  • the resulting precipitates were collected by filtration and dried to give 1-(p-tolyl)cyclobutan-1-amine hydrochloride as white solid (1.860 g, 60.4 %).
  • 1-(p-tolyl)cyclobutan-1-amine hydrochloride 1.000 g, 5.058 mmol
  • ethyl 2-chloropyrimidine-5-carboxylate 0.91 g, 5.311 mmol
  • N,N-diisopropylethylamine 2.643 mL, 15.174 mmol
  • the reaction mixture was concentrated under the reduced pressure to remove the solvent.
  • N'-(2,2-difluoroacetyl)-2-((1-(p-tolyl)cyclobutyl)amino)pyrimidine-5-carbohydrazide (0.360 g, 0.959 mmol) and 1-methoxy-N-triethylammoniosulfonyl-methanimidate (Burgess reagent, 0.343 g, 1.439 mmol) in tetrahydrofuran (5 mL) was mixed at the room temperature, heated at 150 °C under the microwaves for 30 min, and cooled down to the room temperature to terminate reaction. The reaction mixture was concentrated under the reduced pressure to remove the solvent.
  • Example 32 Compound 1676, N-(1-(p-tolyl)cyclobutyl)-5-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)pyrimidin-2-amine
  • Example 33 Compound 1677, Benzyl 4-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyrimidin-2-yl)amino)-4-phenylpiperidine-1-carboxylate
  • the concentrate was diluted with water (200 mL) stirred at the ambient temperature.
  • the resulting precipitates were collected by filtration, washed by water, and dried to give benzyl 4-carbamoyl-4-phenylpiperidine-1-carboxylate as white solid (1.000 g, 63.1 %).
  • the concentrate was diluted with ethyl acetate (20 mL) and was added hydrochloric acid (4.00 M solution in 1,4-dioxane, 6.604 mL, 26.418 mmol) and stirred at the ambient temperature.
  • hydrochloric acid (4.00 M solution in 1,4-dioxane, 6.604 mL, 26.418 mmol) and stirred at the ambient temperature.
  • the resulting precipitates were collected by filtration and dried to give benzyl 4-amino-4-phenylpiperidine-1-carboxylate hydrochloride as white solid (4.000 g, 65.5 %).
  • Example 34 Compound 1678, 5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-N-(4-phenylpiperidin-4-yl)pyrimidin-2-amine
  • Example 35 Compound 1683, 5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-N-(1-(2-fluorophenyl)cyclopropyl)pyrimidin-2-amine
  • Example 36 Compound 1711, 5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-N-(1-(4-fluorophenyl)cyclopropyl)pyrimidin-2-amine
  • N'-(2,2-difluoroacetyl)-2-((1-(4-fluorophenyl)cyclopropyl)amino)pyrimidine-5-carbohydrazide (0.105 g, 0.287 mmol) and 1-methoxy-N-triethylammoniosulfonyl-methanimidate (Burgess reagent, 0.103 g, 0.431 mmol) were mixed at the room temperature in tetrahydrofuran (4 mL), stirred at 100 °C for 17 hr and cooled down to the room temperature. The reaction mixture was concentrated under the reduced pressure to remove the solvent. Water was added to the reaction mixture, followed by extraction with dichloromethane.
  • the bi-phasic mixture was passed through a plastic frit to remove the solid residues and aqueous layer, and the organic layer collected was concentrated in vacuo.
  • Example 37 Compound 1712, N-(1-(4-fluorophenyl)cyclopropyl)-5-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)pyrimidin-2-amine
  • the bi-phasic mixture was passed through a plastic frit to remove the solid residues and aqueous layer, and the organic layer collected was concentrated in vacuo.
  • Example 38 Compound 1713, 5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-N-(1-(3-fluorophenyl)cyclopropyl)pyrimidin-2-amine
  • N'-(2,2-difluoroacetyl)-2-((1-(3-fluorophenyl)cyclopropyl)amino)pyrimidine-5-carbohydrazide (0.232 g, 0.635 mmol) and 1-methoxy-N-triethylammoniosulfonyl-methanimidate (Burgess reagent, 0.227 g, 0.953 mmol) were mixed at the room temperature in tetrahydrofuran (4 mL), stirred at 100 °C for 17 hr, and cooled down to the room temperature. The reaction mixture was concentrated under the reduced pressure to remove the solvent. Water was added to the concentrate, followed by extraction with dichloromethane.
  • the bi-phasic mixture was passed through a plastic frit to remove the solid residues and aqueous layer, and the organic layer collected was concentrated in vacuo.
  • Example 39 Compound 1714, N-(1-(3-fluorophenyl)cyclopropyl)-5-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)pyrimidin-2-amine
  • Example 40 Compound 1722, N-(1-(3-chloro-4-fluorophenyl)cyclopropyl)-5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyrimidin-2-amine
  • 1-(3-chloro-4-fluorophenyl)cyclopropan-1-amine hydrochloride (2.000 g, 9.006 mmol), ethyl 2-chloropyrimidine-5-carboxylate (1.764 g, 9.456 mmol) and N,N-diisopropylethylamine (4.706 mL, 27.017 mmol) were mixed at the room temperature in 1,4-dioxane (20 mL), stirred at 110 °C for 17 hr, and cooled down to the room temperature. The reaction mixture was concentrated under the reduced pressure to remove the solvent.
  • the bi-phasic mixture was passed through a plastic frit to remove the solid residues and aqueous layer, and the organic layer collected was concentrated in vacuo.
  • the concentrate was diluted with water (10 mL) and dichloromethane (5 mL) and stirred at the ambient temperature. The resulting precipitates were collected by filtration, washed by dichloromethane, and dried to give 2-((1-(3-chloro-4-fluorophenyl)cyclopropyl)amino)-N'-(2,2-difluoroacetyl)pyrimidine-5-carbohydrazide as whtie solid (0.200 g, 80.5 %).
  • Example 41 Compound 1723, N-(1-(3-chloro-4-fluorophenyl)cyclopropyl)-5-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)pyrimidin-2-amine
  • Example 42 Compound 1738, 5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-N-(1-(4-(trifluoromethyl)phenyl)cyclopropyl)pyrimidin-2-amine
  • Example 43 Compound 1740, 5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-N-(1-(3-(trifluoromethyl)phenyl)cyclopropyl)pyrimidin-2-amine
  • Example 44 Compound 1741, 5-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)-N-(1-(3-(trifluoromethyl)phenyl)cyclopropyl)pyrimidin-2-amine
  • Example 45 Compound 1742, 5-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)-N-(1-(4-(trifluoromethyl)phenyl)cyclopropyl)pyrimidin-2-amine
  • Example 46 Compound 1761, 3-(1-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyrimidin-2-yl)amino)cyclobutyl)phenol
  • Example 47 Compound 1779, 5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-N-(1-(3,4-difluorophenyl)cyclopropyl)pyrimidin-2-amine
  • 1-(3,4-difluorophenyl)cyclopropan-1-amine hydrochloride (0.142 g, 0.691 mmol)
  • ethyl 2-chloropyrimidine-5-carboxylate (0.142 g, 0.760 mmol)
  • N,N-diisopropylethylamine 0.361 mL, 2.072 mmol
  • the reaction mixture was concentrated under the reduced pressure to remove the solvent.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PCT/KR2016/011355 2015-10-12 2016-10-11 Oxadiazole amine derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same Ceased WO2017065473A1 (en)

Priority Applications (17)

Application Number Priority Date Filing Date Title
MX2018004447A MX384527B (es) 2015-10-12 2016-10-11 Compuestos derivados de oxadiazolamina como inhibidores de histona desacetilasa 6, y la composición farmacéutica que comprende los mismos
PL16855690.0T PL3362445T3 (pl) 2015-10-12 2016-10-11 Związki będące pochodnymi oksadiazoloamin jako inhibitor deacetylazy histonowej 6 oraz kompozycja farmaceutyczna obejmujące takie związki
DK16855690.0T DK3362445T3 (da) 2015-10-12 2016-10-11 Oxadiazolaminderivatforbindelser som histondeacetylase 6-inhibitor, og den farmaceutiske sammensætning dermed
RU2018117502A RU2695133C1 (ru) 2015-10-12 2016-10-11 Производные оксадиазоламина в качестве ингибитора гистондеацетилазы 6 и содержащая их фармацевтическая композиция
MYPI2018701042A MY196174A (en) 2015-10-12 2016-10-11 Oxadiazole Amine Derivative Compounds as Histone Deacetylase 6 Inhibitor, and the Pharmaceutical Composition Comprising the Same
CA3001666A CA3001666C (en) 2015-10-12 2016-10-11 Oxadiazole amine derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
FIEP16855690.0T FI3362445T3 (fi) 2015-10-12 2016-10-11 Oksadiatsoliamiinijohdannaisyhdisteitä histonideasetylaasi 6:n inhibiittoreina ja niitä käsittävä farmaseuttinen koostumus
HRP20230201TT HRP20230201T1 (hr) 2015-10-12 2016-10-11 Oksadiazol aminski spojevi derivati kao inhibitor histonske deacetilaze 6 i farmaceutska kompozicija koja sadrži iste
BR112018007289-3A BR112018007289B1 (pt) 2015-10-12 2016-10-11 Compostos de derivado de oxadiazol amina como inibidor de histona desacetilase 6 e a composição farmacêutica que compreende os mesmos
JP2018518487A JP6697074B2 (ja) 2015-10-12 2016-10-11 ヒストン脱アセチル化酵素６阻害剤としてのオキサジアゾールアミン誘導体化合物及びこれを含有する薬剤学的組成物
ES16855690T ES2940413T3 (es) 2015-10-12 2016-10-11 Compuestos derivados de oxadiazolamina como inhibidores de histona desacetilasa 6, y la composición farmacéutica que los comprende
NZ740809A NZ740809A (en) 2015-10-12 2016-10-11 Oxadiazole amine derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
AU2016338118A AU2016338118B2 (en) 2015-10-12 2016-10-11 Oxadiazole amine derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
EP16855690.0A EP3362445B1 (en) 2015-10-12 2016-10-11 Oxadiazole amine derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
US15/763,972 US10494355B2 (en) 2015-10-12 2016-10-11 Oxadiazole amine derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
CN201680072029.8A CN108699048B (zh) 2015-10-12 2016-10-11 作为组蛋白脱乙酰基酶6抑制剂的噁二唑胺衍生物化合物及包含所述化合物的药物组合物
PH12018500773A PH12018500773A1 (en) 2015-10-12 2018-04-10 Oxadiazole amine derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20150142014 2015-10-12
KR10-2015-0142014 2015-10-12

Publications (1)

Publication Number Publication Date
WO2017065473A1 true WO2017065473A1 (en) 2017-04-20

Family

ID=58517488

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2016/011355 Ceased WO2017065473A1 (en) 2015-10-12 2016-10-11 Oxadiazole amine derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same

Country Status (21)

Country Link
US (1) US10494355B2 (https=)
EP (1) EP3362445B1 (https=)
JP (1) JP6697074B2 (https=)
KR (1) KR101839137B1 (https=)
CN (1) CN108699048B (https=)
AU (1) AU2016338118B2 (https=)
CA (1) CA3001666C (https=)
DK (1) DK3362445T3 (https=)
ES (1) ES2940413T3 (https=)
FI (1) FI3362445T3 (https=)
HR (1) HRP20230201T1 (https=)
HU (1) HUE061967T2 (https=)
MX (1) MX384527B (https=)
MY (1) MY196174A (https=)
NZ (1) NZ740809A (https=)
PH (1) PH12018500773A1 (https=)
PL (1) PL3362445T3 (https=)
PT (1) PT3362445T (https=)
RU (1) RU2695133C1 (https=)
TW (1) TWI694073B (https=)
WO (1) WO2017065473A1 (https=)

Cited By (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018165520A1 (en) * 2017-03-10 2018-09-13 Vps-3, Inc. Metalloenzyme inhibitor compounds
US10112915B2 (en) 2015-02-02 2018-10-30 Forma Therapeutics, Inc. 3-aryl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors
US10183934B2 (en) 2015-02-02 2019-01-22 Forma Therapeutics, Inc. Bicyclic [4,6,0] hydroxamic acids as HDAC inhibitors
US10464911B2 (en) 2015-07-27 2019-11-05 Chong Kun Dang Pharmaceutical Corp. 1,3,4-oxadiazole sulfamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
US10494355B2 (en) 2015-10-12 2019-12-03 Chong Kun Dang Pharmaceutical Corp. Oxadiazole amine derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
US10538498B2 (en) 2015-07-27 2020-01-21 Chong Kun Dang Pharmaceutical Corp. 1,3,4-oxadiazole sulfonamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
WO2020022794A1 (en) 2018-07-26 2020-01-30 Chong Kun Dang Pharmaceutical Corp. 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and pharmaceutical composition comprising the same
US10555935B2 (en) 2016-06-17 2020-02-11 Forma Therapeutics, Inc. 2-spiro-5- and 6-hydroxamic acid indanes as HDAC inhibitors
US10584117B2 (en) 2015-07-27 2020-03-10 Chong Kun Dang Pharmaceutical Corp. 1,3,4-oxadiazole amide derivative compound as histone deacetylase 6 inhibitor, and pharmaceutical composition containing same
WO2020127974A1 (en) 2018-12-21 2020-06-25 Bayer Aktiengesellschaft 1,3,4-oxadiazoles and their derivatives as new antifungal agents
US10717716B2 (en) 2015-08-04 2020-07-21 Chong Kun Dang Pharmaceutical Corp. 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
WO2020158762A1 (ja) * 2019-01-30 2020-08-06 武田薬品工業株式会社 複素環化合物
CN111848423A (zh) * 2019-04-30 2020-10-30 尚科生物医药（上海）有限公司 3-氧代环丁基氨基甲酸叔丁酯的制备方法
WO2021127643A1 (en) * 2019-12-20 2021-06-24 Tenaya Therapeutics, Inc. Fluoroalkyl-oxadiazoles and uses thereof
WO2021133957A1 (en) * 2019-12-27 2021-07-01 Onkure, Inc. Benzimidazole compounds as hdac6 inhibitors
WO2021255089A1 (en) 2020-06-19 2021-12-23 Bayer Aktiengesellschaft 1,3,4-oxadiazole pyrimidines and 1,3,4-oxadiazole pyridines as fungicides
WO2021255091A1 (en) 2020-06-19 2021-12-23 Bayer Aktiengesellschaft 1,3,4-oxadiazoles and their derivatives as fungicides
WO2021255093A1 (en) 2020-06-19 2021-12-23 Bayer Aktiengesellschaft Active compound combination
WO2021255169A1 (en) 2020-06-19 2021-12-23 Bayer Aktiengesellschaft 1,3,4-oxadiazole pyrimidines as fungicides
WO2021255170A1 (en) 2020-06-19 2021-12-23 Bayer Aktiengesellschaft 1,3,4-oxadiazole pyrimidines as fungicides
WO2022029041A1 (en) 2020-08-07 2022-02-10 Italfarmaco S.P.A. 2-(4-((5-(benzo[b]thiophen-3-yl)-1h-tetrazol-1-yl)methyl)phenyl)-5-(difluoromethyl)-1,3,4-oxadiazole derivatives and similar compounds as selective inhibitors of histone deacetylase 6 (hdac6) for use in treating e.g. peripheral neuropathy
WO2022235842A1 (en) * 2021-05-04 2022-11-10 Tenaya Therapeutics, Inc. 2-fluoroalkyl-1,3,4-oxadiazol-5-yl-thiazol, hdac6 inhibitors for use in the treatment of metabolic disease and hfpef
WO2024033293A1 (en) * 2022-08-08 2024-02-15 Italfarmaco S.P.A. Difluoro- and trifluoro-acetyl hydrazides as selective hdac6 inhibitors
US11919879B2 (en) 2021-06-16 2024-03-05 Celgene Corporation Carboxylic acid containing azetidinyl compounds for the treatment of neurodegenerative diseases
US12440484B2 (en) 2019-05-31 2025-10-14 Chong Kun Dang Pharmaceutical Corporation 1,3,4-oxadiazole homophthalimide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
EP4426285A4 (en) * 2021-11-04 2025-10-22 Valo Health Inc HISTONE DEACETYLASE 6 INHIBITOR COMPOUNDS AND USES THEREOF
US12485174B2 (en) 2019-06-27 2025-12-02 The George Washington University, A Congressionally Chartered Not-For-Profit Corporation HDAC6-activated macrophages, compositions, and uses thereof
US12528767B2 (en) 2019-07-30 2026-01-20 Eikonizo Therapeutics, Inc. HDAC6 inhibitors and uses thereof
US12590084B2 (en) 2022-04-08 2026-03-31 Eikonizo Therapeutics, Inc. Oxadiazole HDAC6 inhibitors and uses thereof

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022003490A (es) 2019-09-27 2022-04-25 Takeda Pharmaceuticals Co Derivados de 2-isoindol-1,3,4-oxadiazol utiles como inhibidores de la histona desacetilasa 6 (hdac6).
EP4308097A4 (en) * 2021-03-15 2025-08-20 Univ Michigan Regents NON-HYDROXAMATE HDAC6 INHIBITORS AND METHODS OF USE THEREOF
EP4326263A1 (en) 2021-04-23 2024-02-28 Tenaya Therapeutics, Inc. Hdac6 inhibitors for use in the treatment of dilated cardiomyopathy
CN115572244B (zh) * 2021-06-21 2024-04-30 复旦大学 2’-芳基查尔酮类化合物及其制备方法和在制药中的用途
CN115286615A (zh) * 2022-09-01 2022-11-04 深圳市真味生物科技有限公司 一种消旋尼古丁的制备方法
CN117986146A (zh) * 2023-12-22 2024-05-07 河南优凯制药有限公司 一种枸橼酸喷托维林杂质的制备方法及其检测方法
WO2025215092A1 (en) 2024-04-10 2025-10-16 Institut National de la Santé et de la Recherche Médicale Selective hdac6 inhibitors for use in the treatment of myotonic dystrophy type 1
WO2025250930A1 (en) * 2024-05-31 2025-12-04 Baerenkraft Therapeutics, Llc. Hdac6 inhibitors and method of their use

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007032445A1 (ja) * 2005-09-16 2007-03-22 Kyowa Hakko Kogyo Co., Ltd. タンパク質キナーゼ阻害剤
WO2011088181A1 (en) 2010-01-13 2011-07-21 Tempero Pharmaceuticals, Inc. Compounds and methods
WO2011133888A1 (en) 2010-04-23 2011-10-27 Cytokinetics, Inc. Certain amino-pyrimidines, compositions thereof, and methods for their use
US20120027874A1 (en) * 2010-05-12 2012-02-02 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
CN104744446A (zh) * 2013-12-30 2015-07-01 广东东阳光药业有限公司 杂芳化合物及其在药物中的应用

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4871753A (en) 1986-12-12 1989-10-03 Ciba-Geigy Corporation 3-Phenyl-5-trifluoromethyl-1,2,4-oxadiazole compounds which are useful pesticides
KR100265385B1 (ko) 1998-02-27 2000-11-01 윤여표 순환기 질환의 예방 및 치료 효능을 갖는 홍경천 추출물
US7868204B2 (en) 2001-09-14 2011-01-11 Methylgene Inc. Inhibitors of histone deacetylase
US6897220B2 (en) 2001-09-14 2005-05-24 Methylgene, Inc. Inhibitors of histone deacetylase
WO2003028729A2 (en) 2001-10-03 2003-04-10 Pharmacia Corporation Prodrugs of substituted polycyclic compounds useful for selective inhibition of the coagulation cascade
CN1289469C (zh) 2001-12-20 2006-12-13 布里斯托尔-迈尔斯斯奎布公司 α－(N－磺酰氨基)乙酰胺衍生物作为β－淀粉样蛋白抑制剂
EA200800321A1 (ru) 2005-07-14 2008-06-30 Такеда Сан Диего, Инк. Ингибиторы гистондеацетилазы
EP1910385B1 (en) 2005-08-04 2013-07-24 Sirtris Pharmaceuticals, Inc. Benzothiazoles and thiazolopyridines as sirtuin modulators
BRPI0709110A2 (pt) 2006-03-23 2011-06-28 Prolysis Ltd agentes antibacterianos
WO2007143822A1 (en) 2006-06-14 2007-12-21 Methylgene Inc. Sulfamide and sulfamate derivatives as histone deacetylase inhibitors
EP1878730A1 (en) 2006-07-12 2008-01-16 Bayer Schering Pharma Aktiengesellschaft Substituted isoxazolines, pharmaceutical compositions containing the same, methods of preparing the same, and uses of the same
MX2009006202A (es) 2006-12-11 2009-06-22 Genentech Inc Composiciones y metodos para el tratamiento de neoplasma.
ES2395581T3 (es) 2007-06-20 2013-02-13 Merck Sharp & Dohme Corp. Inhibidores de quinasas janus
WO2009010479A2 (en) 2007-07-13 2009-01-22 Euroscreen S.A. Heterocyclic methylene piperidine derivatives and their use
KR100903743B1 (ko) 2007-08-28 2009-06-19 전병태 소화기계 질환개선 및 예방용 식품 조성물
US8530480B2 (en) 2007-09-04 2013-09-10 The Scripps Research Institute Substituted pyrimidinyl-amines as protein kinase inhibitors
BRPI0817897A2 (pt) 2007-11-02 2019-09-24 Methylgene Inc composto, composição, e, métodos de inibição da atividade hdac, e de tratamento de uma doença responsiva a um inibidor de atividade hdac
EP2207811B1 (en) 2007-11-02 2017-01-04 Momenta Pharmaceuticals, Inc. Non-anticoagulant polysaccharide compositions
RU2515611C2 (ru) 2008-07-23 2014-05-20 Президент Энд Феллоуз Оф Гарвард Колледж Ингибиторы деацетилазы и их применение
EP2421528A4 (en) 2009-04-20 2012-10-17 Inst Oneworld Health COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING 1,3,4-OXADIAZOLE DERIVATIVES
WO2010126002A1 (ja) 2009-04-28 2010-11-04 塩野義製薬株式会社 ヘテロ環スルホンアミド化合物を含有する医薬
JP2011008205A (ja) 2009-05-27 2011-01-13 Fujifilm Corp 二軸性光学異方性膜を作製するための組成物
JP2013517281A (ja) 2010-01-13 2013-05-16 テンペロ、ファーマシューティカルズ、インコーポレイテッド 化合物及び方法
CN103108867A (zh) 2010-02-25 2013-05-15 皮拉马尔企业有限公司 噁二唑化合物及其制备和用途
US8697739B2 (en) 2010-07-29 2014-04-15 Novartis Ag Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof
WO2012076989A1 (en) 2010-12-09 2012-06-14 Wockhardt Limited Ketolide compounds
KR101262870B1 (ko) 2011-01-28 2013-05-09 환인제약 주식회사 호장근 추출물을 함유하는 호흡기 질환의 예방 또는 치료용 조성물
CN103764635B (zh) 2011-07-08 2016-01-20 诺华股份有限公司 新的三氟甲基-噁二唑衍生物及其在疾病治疗中的用途
US9512083B2 (en) 2011-07-20 2016-12-06 The General Hospital Corporation Histone deacetylase 6 selective inhibitors for the treatment of bone disease
WO2013066839A2 (en) * 2011-10-31 2013-05-10 Glaxosmithkline Llc Compounds and methods
WO2013066835A2 (en) 2011-10-31 2013-05-10 Glaxosmithkline Llc Compounds and methods
WO2013066833A1 (en) 2011-10-31 2013-05-10 Glaxosmithkline Llc Compounds and methods to inhibit histone deacetylase (hdac) enzymes
CA2856334A1 (en) 2011-11-28 2013-06-06 Christina Hebach Novel trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease
JP6272773B2 (ja) 2011-11-29 2018-01-31 ナンジン アルゲン ファルマ カンパニー リミテッドＮａｎｊｉｎｇ Ａｌｌｇｅｎ Ｐｈａｒｍａ Ｃｏ． Ｌｔｄ． Ｈｄａｃ６阻害剤・抗腫瘍剤用複素環アミド化合物
SI3041828T1 (sl) 2013-09-06 2018-10-30 Aurigene Discovery Technologies Limited 1,3,4-oksadiazolni in 1,3,4-tiadiazolni derivati kot imunomodulatorji
ES2704704T3 (es) 2013-12-12 2019-03-19 Chong Kun Dang Pharmaceutical Corp Nuevos derivados de azaindol como inhibidores selectivos de la histona desacetilasa (HDAC) y composiciones farmacéuticas que los comprenden
WO2016082930A1 (en) 2014-11-24 2016-06-02 Grünenthal GmbH Substituted oxazole- and thiazole-based carboxamide and urea derivatives as vanilloid receptor ligands ii
CN106349451B (zh) 2015-07-14 2020-11-13 罗门哈斯公司 用于制备疏水改性环氧烷氨基甲酸酯聚合物的方法
FI3328843T3 (fi) 2015-07-27 2023-01-31 1,3,4-oksadiatsolisulfonamidijohdannaisyhdisteitä histonideasetylaasi-6:n inhibiittoreina ja samaa käsittävä farmaseuttinen koostumus
DK3330259T3 (da) 2015-07-27 2020-08-10 Chong Kun Dang Pharmaceutical Corp 1,3,4-oxadiazolamidderivativ-forbindelse som histondeacetylase-6-inhibitor og farmaceutisk sammensætning indeholdende denne
ES2774510T3 (es) 2015-07-27 2020-07-21 Chong Kun Dang Pharmaceutical Corp Derivados de 1,3,4-oxadiazol sulfamida como inhibidores de histona desacetilasa 6 y composición farmacéutica que comprende los mismos
RU2709207C2 (ru) 2015-08-04 2019-12-17 Чонг Кун Данг Фармасьютикал Корп. 1,3,4-оксадиазольные производные соединения в качестве ингибитора гистондеацетилазы 6 и фармацевтическая композиция, содержащая их
HRP20230201T1 (hr) 2015-10-12 2023-03-31 Chong Kun Dang Pharmaceutical Corp. Oksadiazol aminski spojevi derivati kao inhibitor histonske deacetilaze 6 i farmaceutska kompozicija koja sadrži iste

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007032445A1 (ja) * 2005-09-16 2007-03-22 Kyowa Hakko Kogyo Co., Ltd. タンパク質キナーゼ阻害剤
WO2011088181A1 (en) 2010-01-13 2011-07-21 Tempero Pharmaceuticals, Inc. Compounds and methods
WO2011133888A1 (en) 2010-04-23 2011-10-27 Cytokinetics, Inc. Certain amino-pyrimidines, compositions thereof, and methods for their use
US20120027874A1 (en) * 2010-05-12 2012-02-02 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
CN104744446A (zh) * 2013-12-30 2015-07-01 广东东阳光药业有限公司 杂芳化合物及其在药物中的应用

Non-Patent Citations (17)

* Cited by examiner, † Cited by third party
Title
"Kulinkovich-Szymoniak Reaction", J. ORG. CHEM., vol. 67, 2002, pages 3965
"Remington's Pharmaceutical Science", MACK PUBLISHING COMPANY
BOLDEN ET AL., NAT. REV. DRUG DISCOV., vol. 5, no. 9, 2006, pages 769 - 784
HARISH RAJAK, BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 21, 2011, pages 5735 - 5738
HASSIG ET AL., CURR. OPIN. CHEM. BIOL., vol. 1, 1997, pages 300 - 308
HU ET AL., J. NEUROL. SCI., vol. 304, 2011, pages 1 - 8
MATTHIAS ET AL., MOL. CELL. BIOL., vol. 28, 2008, pages 1688 - 1701
METHOT ET AL., BIOORG. MED. CHEM. LETT., vol. 18, 2008, pages 973 - 978
PIEKARZ ET AL., PHARMACEUTICALS, vol. 3, 2010, pages 2751 - 2767
RAJAK, H. ET AL.: "2,5-Disubstituted-1,3,4-oxadiazoles/thiadiazole as surface recognition moiety: Design and synthesis of novel hydroxamic acid based histone deacetylase inhibitors", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 21, 2011, pages 5735 - 5738, XP028286354 *
SANTO ET AL., BLOOD, vol. 119, 2012, pages 2579 - 258
VISHWAKARMA ET AL., INTERNATIONAL IMMUNOPHARMACOLOGY, vol. 16, 2013, pages 72 - 78
WARRELL ET AL., J. NATL. CANCER INST., vol. 90, 1998, pages 1621 - 1625
WIEST ET AL., J. ORG. CHEM., vol. 78, 2013, pages 5051 - 5065
WITT ET AL., CANCER LETTERS, vol. 277, 2009, pages 8 - 21
WOSTER ET AL., MED. CHEM. COMMUN., 2015
YAO ET AL., MOL. CELL, vol. 18, 2005, pages 601 - 607

Cited By (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10988450B2 (en) 2015-02-02 2021-04-27 Valo Early Discovery, Inc. 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors
US11891365B2 (en) 2015-02-02 2024-02-06 Valo Health, Inc. 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors
US10183934B2 (en) 2015-02-02 2019-01-22 Forma Therapeutics, Inc. Bicyclic [4,6,0] hydroxamic acids as HDAC inhibitors
US10214500B2 (en) 2015-02-02 2019-02-26 Forma Therapeutics, Inc. 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors
US10214501B2 (en) 2015-02-02 2019-02-26 Forma Therapeutics, Inc. 3-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors
US10239845B2 (en) 2015-02-02 2019-03-26 Forma Therapeutics, Inc. 3-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors
US12304904B2 (en) 2015-02-02 2025-05-20 Valo Health, Inc. Bicyclic [4,6,0] hydroxamic acids as HDAC inhibitors
US10377726B2 (en) 2015-02-02 2019-08-13 Forma Therapeutics, Inc. 3-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors
US10407418B2 (en) 2015-02-02 2019-09-10 Forma Therapeutics, Inc. Bicyclic [4,6,0] hydroxamic acids as HDAC inhibitors
US10414738B2 (en) 2015-02-02 2019-09-17 Forma Therapeutics, Inc. 3-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors
US10421732B2 (en) 2015-02-02 2019-09-24 Forma Therapeutics, Inc. 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors
US10421731B2 (en) 2015-02-02 2019-09-24 Forma Therapeutics, Inc. 3-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors
US10428031B2 (en) 2015-02-02 2019-10-01 Forma Therapeutics, Inc. 3-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors
US10442776B2 (en) 2015-02-02 2019-10-15 Forma Therapeutics, Inc. 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors
US10450283B2 (en) 2015-02-02 2019-10-22 Forma Therapeutics, Inc. 3-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors
US10450284B2 (en) 2015-02-02 2019-10-22 Forma Therapeutics, Inc. 3-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors
US10457652B2 (en) 2015-02-02 2019-10-29 Forma Therapeutics, Inc. 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors
US12264137B2 (en) 2015-02-02 2025-04-01 Valo Health, Inc. 3-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors
US10112915B2 (en) 2015-02-02 2018-10-30 Forma Therapeutics, Inc. 3-aryl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors
US10464910B2 (en) 2015-02-02 2019-11-05 Forma Therapeutics, Inc. 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors
US10472337B2 (en) 2015-02-02 2019-11-12 Forma Therapeutics, Inc. 3-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors
US10479772B2 (en) 2015-02-02 2019-11-19 Forma Therapeutics, Inc. 3-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors
US10494351B2 (en) 2015-02-02 2019-12-03 Forma Therapeutics, Inc. 3-aryl-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors
US11702412B2 (en) 2015-02-02 2023-07-18 Valo Health, Inc. Bicyclic [4,6,0] hydroxamic acids as HDAC inhibitors
US10494352B2 (en) 2015-02-02 2019-12-03 Forma Therapeutics, Inc. 3-aryl-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors
US10494353B2 (en) 2015-02-02 2019-12-03 Forma Therapeutics, Inc. 3-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors
US10494354B2 (en) 2015-02-02 2019-12-03 Forma Therapeutics, Inc. 3-aryl-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors
US10501424B2 (en) 2015-02-02 2019-12-10 Forma Therapeutics, Inc. 3-aryl-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors
US10513501B2 (en) 2015-02-02 2019-12-24 Forma Therapeutics, Inc. 3-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors
US11279681B2 (en) 2015-02-02 2022-03-22 Valo Health, Inc. 3-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors
US11274084B2 (en) 2015-02-02 2022-03-15 Valo Health, Inc. 3-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors
US11274085B2 (en) 2015-02-02 2022-03-15 Valo Health, Inc. 3-aryl-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors
US10464909B2 (en) 2015-02-02 2019-11-05 Forma Therapeutics, Inc. 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors
US10870645B2 (en) 2015-02-02 2020-12-22 Valo Early Discovery, Inc. Bicyclic [4,6,0] hydroxamic acids as HDAC inhibitors
US10829462B2 (en) 2015-02-02 2020-11-10 Valo Early Discovery, Inc. 3-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors
US10822316B2 (en) 2015-02-02 2020-11-03 Valo Early Discovery, Inc. 3-aryl-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors
US10584117B2 (en) 2015-07-27 2020-03-10 Chong Kun Dang Pharmaceutical Corp. 1,3,4-oxadiazole amide derivative compound as histone deacetylase 6 inhibitor, and pharmaceutical composition containing same
US10538498B2 (en) 2015-07-27 2020-01-21 Chong Kun Dang Pharmaceutical Corp. 1,3,4-oxadiazole sulfonamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
US10464911B2 (en) 2015-07-27 2019-11-05 Chong Kun Dang Pharmaceutical Corp. 1,3,4-oxadiazole sulfamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
US10717716B2 (en) 2015-08-04 2020-07-21 Chong Kun Dang Pharmaceutical Corp. 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
US10494355B2 (en) 2015-10-12 2019-12-03 Chong Kun Dang Pharmaceutical Corp. Oxadiazole amine derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
US12213969B2 (en) 2016-06-17 2025-02-04 Valo Health, Inc. 2-spiro-5- and 6-hydroxamic acid indanes as HDAC inhibitors
US10874649B2 (en) 2016-06-17 2020-12-29 Valo Early Discovery, Inc. 2-spiro-5- and 6-hydroxamic acid indanes as HDAC inhibitors
US11730721B2 (en) 2016-06-17 2023-08-22 Valo Health, Inc. 2-spiro-5- and 6-hydroxamic acid indanes as HDAC inhibitors
US10555935B2 (en) 2016-06-17 2020-02-11 Forma Therapeutics, Inc. 2-spiro-5- and 6-hydroxamic acid indanes as HDAC inhibitors
US10357493B2 (en) 2017-03-10 2019-07-23 Selenity Therapeutics (Bermuda), Ltd. Metalloenzyme inhibitor compounds
WO2018165520A1 (en) * 2017-03-10 2018-09-13 Vps-3, Inc. Metalloenzyme inhibitor compounds
US12370194B2 (en) 2017-03-10 2025-07-29 Eikonizo Therapeutics, Inc. Metalloenzyme inhibitor compounds
US11938134B2 (en) 2017-03-10 2024-03-26 Eikonizo Therapeutics, Inc. Metalloenzyme inhibitor compounds
US11958844B2 (en) 2018-07-26 2024-04-16 Chong Kun Dang Pharmaceutical Corp. 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and pharmaceutical composition comprising the same
EP3827004A4 (en) * 2018-07-26 2022-06-08 Chong Kun Dang Pharmaceutical Corp. 1,3,4-OXADIAZOLE DERIVATIVE COMPOUNDS AS HISTONEDEACETYLASE-6 INHIBITORS AND PHARMACEUTICAL COMPOSITION THEREOF
WO2020022794A1 (en) 2018-07-26 2020-01-30 Chong Kun Dang Pharmaceutical Corp. 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and pharmaceutical composition comprising the same
WO2020127974A1 (en) 2018-12-21 2020-06-25 Bayer Aktiengesellschaft 1,3,4-oxadiazoles and their derivatives as new antifungal agents
US12084436B2 (en) 2019-01-30 2024-09-10 Takeda Pharmaceutical Company Limited Heterocyclic compound
WO2020158762A1 (ja) * 2019-01-30 2020-08-06 武田薬品工業株式会社 複素環化合物
JP7470058B2 (ja) 2019-01-30 2024-04-17 武田薬品工業株式会社 複素環化合物
JPWO2020158762A1 (ja) * 2019-01-30 2021-12-02 武田薬品工業株式会社 複素環化合物
CN111848423A (zh) * 2019-04-30 2020-10-30 尚科生物医药（上海）有限公司 3-氧代环丁基氨基甲酸叔丁酯的制备方法
CN111848423B (zh) * 2019-04-30 2022-10-14 尚科生物医药（上海）有限公司 3-氧代环丁基氨基甲酸叔丁酯的制备方法
US12440484B2 (en) 2019-05-31 2025-10-14 Chong Kun Dang Pharmaceutical Corporation 1,3,4-oxadiazole homophthalimide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
US12485174B2 (en) 2019-06-27 2025-12-02 The George Washington University, A Congressionally Chartered Not-For-Profit Corporation HDAC6-activated macrophages, compositions, and uses thereof
US12528767B2 (en) 2019-07-30 2026-01-20 Eikonizo Therapeutics, Inc. HDAC6 inhibitors and uses thereof
CN114980887A (zh) * 2019-12-20 2022-08-30 特纳亚治疗股份有限公司 氟代烷基-噁二唑及其用途
US12312345B2 (en) 2019-12-20 2025-05-27 Tenaya Therapeutics, Inc. Fluoroalkyl-oxadiazoles and uses thereof
WO2021127643A1 (en) * 2019-12-20 2021-06-24 Tenaya Therapeutics, Inc. Fluoroalkyl-oxadiazoles and uses thereof
US11926622B2 (en) 2019-12-20 2024-03-12 Tenaya Therapeutics, Inc. Fluoroalkyl-oxadiazoles and uses thereof
US11578066B1 (en) 2019-12-20 2023-02-14 Tenaya Therapeutics, Inc. Fluoroalkyl-oxadiazoles and uses thereof
US11339150B2 (en) 2019-12-27 2022-05-24 Onkure, Inc. Benzimidazole compounds as HDAC6 inhibitors
WO2021133957A1 (en) * 2019-12-27 2021-07-01 Onkure, Inc. Benzimidazole compounds as hdac6 inhibitors
WO2021255089A1 (en) 2020-06-19 2021-12-23 Bayer Aktiengesellschaft 1,3,4-oxadiazole pyrimidines and 1,3,4-oxadiazole pyridines as fungicides
WO2021255091A1 (en) 2020-06-19 2021-12-23 Bayer Aktiengesellschaft 1,3,4-oxadiazoles and their derivatives as fungicides
WO2021255169A1 (en) 2020-06-19 2021-12-23 Bayer Aktiengesellschaft 1,3,4-oxadiazole pyrimidines as fungicides
WO2021255170A1 (en) 2020-06-19 2021-12-23 Bayer Aktiengesellschaft 1,3,4-oxadiazole pyrimidines as fungicides
WO2021255093A1 (en) 2020-06-19 2021-12-23 Bayer Aktiengesellschaft Active compound combination
WO2022029041A1 (en) 2020-08-07 2022-02-10 Italfarmaco S.P.A. 2-(4-((5-(benzo[b]thiophen-3-yl)-1h-tetrazol-1-yl)methyl)phenyl)-5-(difluoromethyl)-1,3,4-oxadiazole derivatives and similar compounds as selective inhibitors of histone deacetylase 6 (hdac6) for use in treating e.g. peripheral neuropathy
US12201617B2 (en) 2021-05-04 2025-01-21 Tenaya Therapeutics, Inc. HDAC6 inhibitors for treatment of metabolic disease and HFpEF
WO2022235842A1 (en) * 2021-05-04 2022-11-10 Tenaya Therapeutics, Inc. 2-fluoroalkyl-1,3,4-oxadiazol-5-yl-thiazol, hdac6 inhibitors for use in the treatment of metabolic disease and hfpef
US11919879B2 (en) 2021-06-16 2024-03-05 Celgene Corporation Carboxylic acid containing azetidinyl compounds for the treatment of neurodegenerative diseases
US12552771B2 (en) 2021-06-16 2026-02-17 Celgene Corporation Carboxylic acid containing azetidinyl compounds for the treatment of neurodegenerative diseases
EP4426285A4 (en) * 2021-11-04 2025-10-22 Valo Health Inc HISTONE DEACETYLASE 6 INHIBITOR COMPOUNDS AND USES THEREOF
US12590084B2 (en) 2022-04-08 2026-03-31 Eikonizo Therapeutics, Inc. Oxadiazole HDAC6 inhibitors and uses thereof
WO2024033293A1 (en) * 2022-08-08 2024-02-15 Italfarmaco S.P.A. Difluoro- and trifluoro-acetyl hydrazides as selective hdac6 inhibitors

Also Published As

Publication number Publication date
PL3362445T3 (pl) 2023-08-07
RU2695133C1 (ru) 2019-07-22
US20180273495A1 (en) 2018-09-27
BR112018007289A2 (pt) 2018-10-23
EP3362445A1 (en) 2018-08-22
AU2016338118A1 (en) 2018-04-12
US10494355B2 (en) 2019-12-03
ES2940413T3 (es) 2023-05-08
AU2016338118B2 (en) 2019-03-14
FI3362445T3 (fi) 2023-03-21
TWI694073B (zh) 2020-05-21
TW201716397A (zh) 2017-05-16
EP3362445A4 (en) 2019-05-22
MX384527B (es) 2025-03-14
CA3001666A1 (en) 2017-04-20
EP3362445B1 (en) 2023-01-25
CA3001666C (en) 2021-03-30
MX2018004447A (es) 2018-08-01
KR20170043091A (ko) 2017-04-20
CN108699048B (zh) 2021-12-28
HUE061967T2 (hu) 2023-09-28
JP2018530571A (ja) 2018-10-18
NZ740809A (en) 2019-04-26
KR101839137B1 (ko) 2018-03-26
PH12018500773B1 (en) 2018-10-29
JP6697074B2 (ja) 2020-05-20
PH12018500773A1 (en) 2018-10-29
CN108699048A (zh) 2018-10-23
HRP20230201T1 (hr) 2023-03-31
DK3362445T3 (da) 2023-02-27
MY196174A (en) 2023-03-20
PT3362445T (pt) 2023-03-20

Similar Documents

Publication Publication Date Title
EP3362445A1 (en) Oxadiazole amine derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
EP3328844A1 (en) 1,3,4-oxadiazole sulfamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
AU2014260605B2 (en) Novel compounds for selective histone deacetylase inhibitors, and pharmaceutical composition comprising the same
WO2017018803A1 (en) 1,3,4-oxadiazole sulfonamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
WO2017018804A1 (ko) 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 아마이드 유도체 화합물 및 이를 포함하는 약제학적 조성물
WO2015137750A1 (en) Novel compounds as histone deacetylase 6 inhibitors and pharmaceutical compositions comprising the same
WO2016190630A1 (en) Heterocyclicalkyl derivative compounds as selective histone deacetylase inhibitors and pharmaceutical compositions comprising the same
EP3697787A1 (en) Heterocyclic compound as a protein kinase inhibitor
WO2013081400A2 (ko) 신규한 벤즈아마이드 유도체 및 그 용도
EP2566859A2 (en) Picolinamide and pyrimidine-4-carboxamide compounds, process for preparing and pharmaceutical composition comprising the same
WO2021172887A1 (en) 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
AU2019310508A1 (en) 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and pharmaceutical composition comprising the same
WO2019054766A1 (en) COMPOUND DERIVED FROM PYRAZOLE AND USE THEREOF
WO2015102426A1 (en) Novel indole derivative compound and pharmaceutical composition comprising the same
WO2020096372A1 (ko) 신규한 피페리딘-2,6-디온 유도체 및 이의 용도
WO2019212256A1 (ko) 신규한 헤테로 사이클 유도체
EP4110780A1 (en) 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
WO2021210857A1 (en) 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
WO2024080792A1 (en) Novel heterobicyclic compound for inhibiting yap-tead interaction and pharmaceutical composition comprising same
EP3423433A1 (en) Sulfamate derivative compounds, processes for preparing them and their uses
WO2012134231A2 (ko) 카나비노이드 수용체（ｃｂ１） 길항제로서의 벤즈아미드 유도체
WO2014021591A2 (ko) 신규한 화합물, 이의 제조방법 및 이를 포함하는 약제학적 조성물
WO2023229378A1 (ko) 다이아실글리세롤 키나아제 저해제로서 헤테로사이클 화합물 및 이의 용도
WO2025150943A1 (ko) 신규 화합물 및 이의 용도
WO2024054071A1 (en) 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16855690

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 15763972

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2018518487

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 12018500773

Country of ref document: PH

ENP Entry into the national phase

Ref document number: 3001666

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: MX/A/2018/004447

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2016338118

Country of ref document: AU

Date of ref document: 20161011

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112018007289

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: 2018117502

Country of ref document: RU

ENP Entry into the national phase

Ref document number: 112018007289

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20180411